CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $155,693
- in 6 filings
Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-17 | Cappello Joseph Chief Technical Officer | Sale | −973 | $5.37 | $5K | 156,060 |
| 2025-11-17 | Smalling Ralph Head of Regulatory | Sale | −343 | $5.37 | $2K | 68,823 |
| 2025-09-03 | Smalling Ralph Head of Regulatory | Sale | −580 | $3.36 | $2K | 69,166 |
| 2025-09-01 | Zindrick Thomas President and CEO | Returned to the company · Stock Option (Right to Buy) | −925,000 | 0 | ||
| 2025-09-01 | Zindrick Thomas President and CEO | Grant or award · Stock Option (Right to Buy) | +925,000 | 925,000 | ||
| 2025-09-01 | Zindrick Thomas President and CEO | Returned to the company · Stock Option (Right to Buy) | −157,372 | 0 | ||
| 2025-09-01 | Zindrick Thomas President and CEO | Grant or award · Stock Option (Right to Buy) | +157,372 | 157,372 | ||
| 2025-09-01 | Zindrick Thomas President and CEO | Returned to the company · Stock Option (Right to Buy) | −23,568 | 0 | ||
| 2025-09-01 | Zindrick Thomas President and CEO | Grant or award · Stock Option (Right to Buy) | +23,568 | 23,568 | ||
| 2025-09-01 | Zindrick Thomas President and CEO | Returned to the company · Stock Option (Right to Buy) | −250,000 | 0 | ||
| 2025-09-01 | Zindrick Thomas President and CEO | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2025-09-01 | Yu Yong SVP, Clinical Development | Returned to the company · Stock Option (Right to Buy) | −207,652 | 0 | ||
| 2025-09-01 | Yu Yong SVP, Clinical Development | Grant or award · Stock Option (Right to Buy) | +207,652 | 207,652 | ||
| 2025-09-01 | Yu Yong SVP, Clinical Development | Returned to the company · Stock Option (Right to Buy) | −65,000 | 0 | ||
| 2025-09-01 | Yu Yong SVP, Clinical Development | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2025-09-01 | Smalling Ralph Head of Regulatory | Grant or award | +10,000 | 70,990 | ||
| 2025-09-01 | Smalling Ralph Head of Regulatory | Returned to the company · Stock Option (Right to Buy) | −8,333 | 0 | ||
| 2025-09-01 | Smalling Ralph Head of Regulatory | Grant or award · Stock Option (Right to Buy) | +8,333 | 8,333 | ||
| 2025-09-01 | Cappello Joseph Chief Technical Officer | Returned to the company · Stock Option (Right to Buy) | −16,666 | 0 | ||
| 2025-09-01 | Cappello Joseph Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +16,666 | 16,666 |
Page 3 of 9 · 170 trades